摘要
目的评价乳腺癌患者在新辅助化疗后行前哨淋巴结活检(SLNB)的临床应用价值。方法回顾性分析我院36例接受新辅助化疗患者后行前哨淋巴结活检的检出率和假阴性率,且进行比较。结果新辅助化疗后患者行SLNB检出率和假阴性率分别为91.7%和10.3%。结论对新辅助化疗后乳腺癌患者行前哨淋巴结活检具有较大的临床价值。
Objective To evaluate the clinical application in breast cancer women receiving sentinel lymph node biopsy after neoadjuvant chemotherapy.Methods Retrospective analysis of the detection rate and false negative rate about 36 breast cancer patients receiving neoadjuvant chemotherapy was analyzed retrospectively.Results The patients receiving neoadjuvant chemotherapy the detection rate and false negative rate was 91.7% and 10.3%.Conclusion Sentinel lymph node biopsy after neoadjuvant chemotherapy has clinical value.
出处
《福建医药杂志》
CAS
2016年第5期1-3,共3页
Fujian Medical Journal
关键词
乳腺肿瘤
前哨淋巴结
检出率
假阴性率
breast cancer
sentinel lymph node
detection rate
false negative rate
